Oxcarbazepine Patent Expiration
Oxcarbazepine is Used for managing partial-onset seizures. It was first introduced by Novartis Pharmaceuticals Corp
Oxcarbazepine Patents
Given below is the list of patents protecting Oxcarbazepine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Oxtellar Xr | US10220042 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US11166960 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US11896599 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US7722898 | Modified-release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US7910131 | Method of treating seizures using modified release formulations of oxcarbazepine | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US8617600 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US8821930 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US9119791 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US9351975 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US9370525 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US9855278 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Trileptal |
US8119148 (Pediatric) | Suspension comprising oxcarbazepine |
Jun 19, 2021
(Expired) | Novartis |
| Trileptal | US8119148 | Suspension comprising oxcarbazepine |
Dec 19, 2020
(Expired) | Novartis |
| Trileptal |
US7037525 (Pediatric) | Oxacarbazepine film-coated tablets |
Aug 12, 2018
(Expired) | Novartis |
| Trileptal | US7037525 | Oxacarbazepine film-coated tablets |
Feb 12, 2018
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Oxcarbazepine's patents.
Latest Legal Activities on Oxcarbazepine's Patents
Given below is the list recent legal activities going on the following patents of Oxcarbazepine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical
| 25 Mar, 2024 | US8119148 |
| Maintenance Fee Reminder Mailed Critical
| 09 Oct, 2023 | US8119148 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Aug, 2019 | US8119148 |
| Expire Patent Critical
| 30 May, 2014 | US7037525 |
| Recordation of Patent Grant Mailed Critical
| 21 Feb, 2012 | US8119148 |
| Patent Issue Date Used in PTA Calculation Critical
| 21 Feb, 2012 | US8119148 |
| Issue Notification Mailed Critical
| 01 Feb, 2012 | US8119148 |
| Dispatch to FDC | 27 Jan, 2012 | US8119148 |
| Dispatch to FDC | 17 Jan, 2012 | US8119148 |
| Application Is Considered Ready for Issue Critical
| 17 Jan, 2012 | US8119148 |
Oxcarbazepine's Family Patents
